Kentville

Researchers are evaluating how well oral icotrokinra works, its safety, and how well patients tolerate it in adults and adolescents with moderately to severely active ulcerative colitis, a chronic condition where the colon lining becomes inflamed and develops ulcers. This is a Phase 3 study aimed at finding effective treatments for this condition using a rigorous comparison. Participants will receive either icotrokinra tablets or placebo tablets taken by mouth. The study includes an induction phase and a maintenance phase, with adults participating in a randomized, double-blind, placebo-controlled design, while adolescents join an open-label maintenance study. Throughout the study, researchers will monitor clinical remission rates at 12 weeks during induction and at 40 weeks during maintenance. Participants will undergo assessments including endoscopic evaluations and pregnancy tests for females of childbearing potential. Safety and tolerability will be closely observed, with the total study duration covering both induction and maintenance periods.

Researchers are evaluating the effectiveness and safety of icotrokinra in adults with moderately to severely active Crohn's disease, a chronic condition causing severe inflammation in the intestinal tract. This Phase 2b/3 study aims to understand how well icotrokinra works compared to a placebo in improving symptoms and intestinal healing in this patient group. Participants will receive either icotrokinra or a matching placebo orally every day. The study includes both induction and maintenance phases where researchers assess clinical and endoscopic responses at specific time points, such as Week 12 and Week 40, to determine treatment effects over time. Throughout the study, participants will undergo various assessments including clinical evaluations, endoscopic exams, and safety monitoring. Researchers will measure outcomes like clinical response, clinical remission, and endoscopic healing at Weeks 12 and 40. The study involves regular monitoring to track the participants' health and treatment adherence over the duration of the trial.

Researchers are evaluating the safety and effectiveness of tulisokibart, a humanized monoclonal antibody, in people with moderately to severely active Crohn's disease. The research includes two studies: Study 1, which has induction and maintenance treatment phases, and Study 2, which only includes induction treatment. The main goals are to see if tulisokibart can help participants achieve clinical remission and endoscopic response compared to placebo, measured at 12 and 52 weeks depending on the study and region (US/FDA or EU/EMA).

Researchers are evaluating the efficacy and safety of SAR441566, an oral tablet medication, in adults with moderate-to-severe ulcerative colitis (UC). This Phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled, dose-ranging study aims to determine how well different doses of SAR441566 help patients achieve clinical remission, measured by the modified Mayo Score, after 12 weeks of treatment. The study includes a screening period lasting up to 28 days plus an additional 7 days if needed. The main treatment period lasts 52 weeks and consists of a 12-week double-blind induction phase followed by a 40-week maintenance phase, ending with a 2-week follow-up after treatment. Participants receive either SAR441566 or a matching placebo orally as tablets. After the main study, eligible participants not joining a long-term study may enter an open-label treatment period for up to 40 weeks. The main study involves 12 visits, and the open-label phase includes 8 visits. During the study, participants will be monitored through clinical assessments and scoring of disease activity. Researchers will track remission rates at week 12 and evaluate long-term safety and efficacy during the maintenance and open-label periods. The total time involved for participants can be up to 59 weeks, including screening, treatment, follow-up, and optional open-label extension.

Spatial neglect is a common condition after stroke that causes difficulty noticing or responding to the left side of the body or space, leading to challenges with daily activities like eating, dressing, and moving around. This condition affects many stroke patients and currently lacks a standard treatment. Researchers are evaluating a new gamified prism adaptation (PA) treatment called Peg-the-Mole (PTM), which can be used at home without daily therapist supervision. This study aims to assess the feasibility and effectiveness of this portable PA treatment in both inpatient and home settings to improve neglect symptoms. Participants will be randomly assigned to one of two groups: one using 15-degree rightward shifting prism goggles (experimental group) and the other using 5-degree shifting goggles (placebo control group). Both groups will complete 10 sessions of a 15-minute aiming task on an iPad over about two weeks. Sessions will take place in the hospital or at home, depending on the participant's length of hospital stay, with a hybrid model if discharged early. The treatment uses a game-like computerized procedure to encourage engagement and adherence. Throughout the study, researchers will assess neglect severity and its impact on daily activities before, immediately after, and one month following the intervention. They will also track treatment feasibility through logs and patient feedback. This includes multiple tests of neglect symptoms at different times and measures of how well patients comply with the treatment. The study will help determine whether this novel PA method can be effectively used in real-world rehabilitation settings to improve recovery and independence after stroke.

Researchers are evaluating whether a low-cost virtual reality (VR) motor rehabilitation platform can improve upper limb motor recovery in adults who have experienced a first-time ischemic stroke. The study focuses on people with moderate to severe upper limb motor deficits and aims to compare VR-based motor therapy to standard care. It also seeks to determine if VR therapy is a practical and acceptable treatment option, especially for those in rural areas with limited access to rehabilitation resources. Participants in the trial may receive VR-guided motor rehabilitation using custom exercises delivered through a Meta Quest 2/3S/3 virtual reality headset. The study includes two groups based on patient location and stroke timing: an inpatient arm for those admitted within 5 weeks of stroke onset at Valley Regional Hospital and an outpatient arm for those discharged home within 3 months of stroke onset living within an hour's drive of the hospital. The intervention involves gamified activities to enhance upper limb movements. During the study, participants undergo standardized assessments of motor function and quality of life at multiple time points. Researchers collect feedback on VR system usability, motion sickness, and patient engagement. Treatment effectiveness is measured both in the hospital (up to day 26) and at home (up to day 47). The study monitors treatment feasibility, patient attitudes toward technology, and engagement throughout the treatment periods to understand the overall impact and practicality of VR therapy for stroke rehabilitation.